Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Issue : Clinical Pharmacist, 2013

Sort by: Newest first Oldest first A-Z Z-A

  • Targeted cancer therapy: hopes and challenges Subscription

    1 JAN 2013 By Libby Hardy

    Targeted cancer therapies have changed the face of oncology and will continue to be a focus for pharmaceutical research. Techniques for identifying molecular targets will become more sophisticated, and it is expected that testing patients’ cancers for the relevant biomarkers will become more affordable and routine in practice.

  • Type 1 diabetes: pathophysiology and diagnosis Subscription

    Comments (4)

    Type 1 diabetes is caused by the autoimmune destruction of the insulin-producing b-cells of the islets of Langerhans. Genetic and environmental factors are thought to play a part in the onset of the disease, which usually occurs in childhood and young adulthood.

  • Type 1 diabetes: insulin management Subscription

    Comments (2)

    Insulin is used by patients with type 1 diabetes to prevent hyperglycaemia and reduce the risk of developing long-term complications. Different types of insulin have different properties and are used in a range of treatment regimens to best suit each individual patient.

  • How to communicate effectively in patients' medical notes Subscription

    1 JAN 2013

    By Sally James, MSc, MRPharmS, and Aine McManus, DipClinPharm

  • Do selective serotonin reuptake inhibitors increase the risk of gastrointestinal bleeding? Subscription

    1 JAN 2013

    What is the risk of gastrointestinal bleeding associated with selective serotonin reuptake inhibitors? Various reviews and meta-analyses indicate that there is a link between selective serotonin reuptake inhibitor (SSRI) use and gastrointestinal (GI) bleeding, particularly upper-GI bleeding.

  • How to obtain NHS approval for research Subscription

    1 JAN 2013

    You have identified a research topic in your specialist area. You have completed a literature review and formulated the research questions or hypothesis. The research protocol is almost ready. So how do you proceed?

  • Make the case for pharmacist prescribing in your organisation Subscription

    1 JAN 2013

    Are you thinking about becoming an independent prescriber? Or have you already qualified but are struggling to get your prescribing service up and running?

  • Hepatitis C: Clinical features and diagnosis Subscription

    1 JAN 2013 By Sarah Knighton

     Hepatitis C is a global health problem and around 3% of the population are believed to carry the virus. Its long-term sequelae include cirrhosis, end-stage liver disease and primary liver cancer and it is the most common reason for liver transplantation in Europe and North America.

  • Hepatitis C: management Subscription

    1 JAN 2013 By Sarah Knighton

    The aim of antiviral therapy for hepatitis C infection is to eradicate the virus completely in order to prevent chronic disease and subsequent liver damage. All patients treated for chronic hepatitis C virus (HCV) infection receive dual therapy with peginterferon and ribavirin. Patients with HCV genotype 1 can also be prescribed a directly acting antiviral, boceprevir or telaprevir, in addition to dual therapy, which offers better cure rates.

  • How to ensure that you report medication incidents effectively Subscription

    1 JAN 2013

    By Nicola Wake, DipClinPharm, MRPharmS

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.